Real-World Effectiveness of MAVacamtEN in Canada (MAVEN): A Retrospective Physician Survey of Patient Charts
Status: Completed
Location: See location...
Intervention Type: Drug
Study Type: Observational
SUMMARY
The purpose of this observational, retrospective, physician survey study is to describe the real-world effectiveness and use of mavacamten in participants who initiated treatment for obstructive hypertrophic cardiomyopathy (oHCM) in Canada.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
View:
• Patients who have initiated mavacamten, as part of routine clinical care, through the Bristol Myers Squibb CAMZYOS Patient Support Program for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM)
• Adult patient (≥18 years of age or as defined per local province/territory) at Index Date (first prescribed dose of mavacamten).
• Patient has been diagnosed with symptomatic oHCM of New York Heart Association (NYHA) class II to III at the time of mavacamten initiation.
Locations
Other Locations
Canada
London Health Science Centre (LHSC)
London
Time Frame
Start Date: 2024-06-24
Completion Date: 2024-12-19
Participants
Target number of participants: 115
Treatments
Patients treated with mavacamten
Patients with symptomatic obstructive hypertrophic cardiomyopathy (NYHA functional class II-III) who receive mavacamten as part of routine clinical care
Related Therapeutic Areas
Sponsors
Leads: Bristol-Myers Squibb